Kazia Therapeutics Ltd - ESG Rating & Company Profile powered by AI
The report of Kazia Therapeutics Ltd was assembled by All Street Sevva using advanced AI. Comprehensive ESG analysis of Kazia Therapeutics Ltd are accessed by signing in. The page displays a zero-cost E,S&G assessment covering Kazia Therapeutics Ltd.
Kazia Therapeutics Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.1; made up of an environmental score of 8.0, social score of 6.4 and governance score of 4.0.
6.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 450 | Valneva USA Inc | 6.2 | High |
| 450 | Sino Biopharmaceutical Ltd | 6.2 | High |
| 483 | Kazia Therapeutics Ltd | 6.1 | High |
| 483 | Bora Pharmaceuticals Co Ltd | 6.1 | High |
| 483 | Affimed NV | 6.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kazia Therapeutics Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Kazia Therapeutics Ltd report the average age of the workforce?
Sign up for free to unlockDoes Kazia Therapeutics Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Kazia Therapeutics Ltd offer flexible work?
Sign up for free to unlockDoes Kazia Therapeutics Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kazia Therapeutics Ltd conduct supply chain audits?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kazia Therapeutics Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose water use targets?
Sign up for free to unlockDoes Kazia Therapeutics Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Kazia Therapeutics Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Kazia Therapeutics Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kazia Therapeutics Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kazia Therapeutics Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kazia Therapeutics Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kazia Therapeutics Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose its waste policy?
Sign up for free to unlockDoes Kazia Therapeutics Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose energy use targets?
Sign up for free to unlockDoes Kazia Therapeutics Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kazia Therapeutics Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kazia Therapeutics Ltd
These potential risks are based on the size, segment and geographies of the company.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.